HOME >> BIOLOGY >> NEWS
Sperm created in the laboratory from embryonic stem cells produce viable progeny

Scientists have demonstrated for the first time that embryonic stem (ES) cells cultured in the laboratory can produce sperm with the capacity to produce viable offspring. The research, published in the July issue of Developmental Cell, opens many exciting avenues for future studies, including investigation of mechanisms involved in sperm production and development of new treatment strategies for infertility.

Previous studies have shown that ES cells grown in the laboratory can differentiate into primordial germ cells that then give rise to cells resembling mature egg and sperm cells, known as gametes. However, the functionality of the gametes has not been thoroughly tested and many questions about the viability of these cells remain unanswered. Dr. Karim Nayernia and Dr. Wolfgang Engel from the Institute of Human Genetics at the University of Goettingen in Goettingen, Germany and colleagues developed a new strategy for generating mature sperm cells in the laboratory using ES cells from mice and went on to test the functionality of the ES-derived sperm.

ES cells were treated with specific factors know to direct sperm production and screened for characteristics associated with primordial and spermatagonial stem cells. The researchers demonstrated that these cells could be further differentiated into mature sperm in the laboratory or could be transplanted into the testes of mice where they retained the capacity develop into sperm. Intra-cytoplasmic injection of the ES-derived sperm into mouse eggs resulted in successful fertilization and the resulting early stage embryos were successfully transplanted into mice. Six of the seven mice born developed into adult mice.

The results of this study establish that the ES cell derived cell lines can produce functional sperm in the laboratory which can be used to successfully fertilize eggs and support full-term development into embryos and adult mice. "Our approach provides an accessible in vitro
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
11-Jul-2006


Page: 1 2

Related biology news :

1. Sperm proteome gives tantalizing glimpse towards the origin of sex
2. Sperm stem cells closer to being like embryonic stem cells
3. Sperm trading can resolve hermaphrodite mating conflicts
4. Sperm enzyme is essential for male fertility, study shows
5. Newly created cancer stem cells could aid breast cancer research
6. Not all embryonic stem cell lines are created equal
7. Early-stage sperm cells created from human bone marrow
8. Researcher examines polymers created with poultry feathers
9. First direct electric link between neurons and light-sensitive nanoparticle films created
10. All itches not created equal -- Different parts of brain activated depending on cause
11. Cloned mice created from fully differentiated cells, a milestone in cloning research

Post Your Comments:
(Date:10/18/2014)... suspected genetic conditions, a certain type of exome sequencing ... than traditional molecular diagnostic methods, according to a study ... released to coincide with the American Society of Human ... protein­coding region of the genome (the complete set of ... organism), has been rapidly applied in research settings and ...
(Date:10/17/2014)... release is available in German . ... of sperms every day in order to reproduce? And why ... the topic of the latest issue of the research journal ... The evolutionary biologist Steven Ramm from Bielefeld University Bielefeld has ... is not unusual for a female to copulate with several ...
(Date:10/17/2014)... To date, antidotes ... doctors are often limited to supportive therapy such as induced ... of drugs involved. So what can be done if a ... professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences at ... "The task was to develop an agent that could eliminate ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Sperm wars 2Emergency aid for overdoses 2Emergency aid for overdoses 3
(Date:10/22/2014)... Oct. 22, 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, announced today that ... Notice of Allowance for a composition of matter patent ... difficile program, SYN-004. This is Synthetic Biologics, first ... U.S. and adds to the Company,s extensive C. ...
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... BOSTON , Oct. 20, 2014 ... commercialization company tackling big healthcare problems, announced today ... investment round, with participation from Invesco Perpetual, a ... be used to drive PureTech,s existing pipeline forward ... technologies. "PureTech has the scientific creativity to really ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
Cached News: